Luc Biedermann

Appearances

EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
Date
May 20, 2024
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
Evan Dellon
University of North Carolina School of Medicine
Speakers
Margaret Collins
Arjan Bredenoord
Amsterdam UMC, University of Amsterdam
Hamish Philpott
Luc Biedermann
Márjori Dulcine
Thai Nguyen-Cleary
Chinyu Su
Jin Yu
Huaming Tan
Fabio Cataldi
Hanzhe Zheng
Wenjin Wang
Pamela Clax
John Woolcott
Ikuo Hirano
RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND STUDY
Date
May 21, 2024
BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Presenter
Stefan Schreiber
Speakers
Remo Panaccione
Gareth Parkes
Laurent Peyrin-Biroulet
Marc Ferrante
Tadakazu Hisamatsu
Britta Siegmund
Charité - Universitätsmedizin Berlin
Jasmina Kalabic
Phillip Levine
Ezequiel Neimark
Kori Wallace
Su Chen
Ling Cheng
W Rachel Duan
Alessandro Armuzzi
Luc Biedermann
Edward Loftus
Mayo Foundation for Medical Education and Research
Gil Melmed
Edouard Louis